The Tyrphostin B42 Inhibits Cell Proliferation and HER-2 Autophosphorylation in Cervical Carcinoma Cell Lines

REFERENCES

• Tkeshelashvili V. T., Bokhman J. V., Kuznetzov V V., Maximov S. J., Chkuaseli G. T. Geographic peculiarities of endometrial and cervical cancer incidence in five continents (review). Eur. J. Gynaecol. Oncol. 1993; 14: 89–94
   PubMedGoogle Scholar
• Howley P. M. Role of the human papilloma viruses in human cancers. Cancer Res. 1991; 51: 5019s–5022s
   PubMed Web of Science ®Google Scholar
• zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat. Rev. Cancer. 2002; 2: 342–350
   PubMed Web of Science ®Google Scholar
• Munoz N., Bosch F. X., de Sanjose S., Herrero R., Castellsaque X., Shah K. V., Snijders P. J., Meijer C. Cervical Cancer Study Group. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N. Engl. J. Med. 2003; 348: 518–527
   Google Scholar
• Stopler M. C., Straight S. W., Tsao G., Schlegel R., McCance D. J. The E5 gene of HPV16 enhances keratinocyte inmortalization by full length DNA. Virology. 1996; 223: 251–254
   PubMed Web of Science ®Google Scholar
• Straight S. W., Humble P. W., Jewers R. J., McCance D. J. The E5 oncoprotein of HPV16 transforms fibroblasts and affects the downregulation of the EGFR in keratinocytes. J. Virol. 1993; 67: 4521–4532
   PubMed Web of Science ®Google Scholar
• Woodworth C. D., McMullin E., Iglesias M., Plowman G. D. Interleukin 1α and TNFα stimulate autocrine amphiregulin expression and proliferation of human papilloma-immortalized and carcinoma derived cervical epithelium cells. Proc. Natl. Acad. Sci. USA. 1995; 92: 2840–2844
   PubMed Web of Science ®Google Scholar
• Ullrich A., Coussens L., Hayflick J. S., Dull T. J., Gray A., Tam A. W., Lee J., Yarden Y., Libermann T. A., Schlessinger J., et al. Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells. Nature 1984; 309: 418–425
   PubMed Web of Science ®Google Scholar
• Yarden Y., Sliwkowski M. X. Untangling the ErbB signaling network. Nat. Rev. Mol. Cell Biol. 2001; 2: 127–137
   PubMed Web of Science ®Google Scholar
• Salomón D. S., Brandt R., Ciardiello F., Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit. Rev. Oncol. Hematol. 1995; 19: 183–232
   PubMed Web of Science ®Google Scholar
• Slamon D. J., Godolphin W., Jones L. A., Holt J. A., Wong S. G., Keith D. E., Levin W. J., Stuart S. G., Udoye J., Ullrich A., et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989; 244: 707–712
   PubMed Web of Science ®Google Scholar
• Yamamoto T., Ikawa S., Akiyama T., Semba K., Nomura N., Miyajima N., Saito T., Toyoshima K. Similarity of protein encoded by the human c-erb-B-2 gene to epidermal growth factor. Nature. 1986; 319: 230–234
   PubMed Web of Science ®Google Scholar
• Lonardo F., Di Marco E., King C. R., Pierce J. H., Segatto O., Aaronson S. A., Di Fiore P. P. The normal erbB-2 product is an atypical receptor-like tyrosine kinase with constitutive activity in the absence of ligand. New Biol. 1990; 2: 992–1003
   PubMedGoogle Scholar
• Carter P., Presta L., Gorman C. M., Ridgway J. B., Henner D., Wong W. L., Rowland A. M., Kotts C., Carver M. E., Shepard H. M. Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc. Natl. Acad. Sci. U S A. 1992; 89: 4285–4289
   PubMed Web of Science ®Google Scholar
• Baselga J., Tripathy D., Mendelsohn J., Baughman S., Benz C. C., Dantis L., Sklarin N. T., Seidman A. D., Hudis C. A., Moore J., Rosen P. P., Twaddell T., Henderson I. C., Norton L. Phase I I study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neu-overexpressing metastatic breast cancer. Semin. Oncol. 1999; 6: 78–83, (4 Suppl 12)
   Google Scholar
• Pegram M. D., Lipton A., Hayes D. F., Weber B. L., Baselga J. M., Tripathy D., Baly D., Baughman S. A., Twaddell T., Glaspy J. A., Slamon D. J. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J. Clin. Oncol. 1998; 16: 2659–2671
   PubMed Web of Science ®Google Scholar
• Ben-Bassat H., Rosenbaum-Mitrani S., Hartzstark Z., Levitzki R., Chaouat M., Shlomai Z., Klein B. Y., Kleinberger-Doron N., Gazit A., Tsvieli R., Levitzki A. Tyrphostins that suppress the growth of human papilloma virus 16-immortalized human keratinocytes. J. Pharmacol. Experimental Ther. 1999; 290: 1442–1457
   PubMed Web of Science ®Google Scholar
• Caceres-Cortes J. R., Alvarado-Moreno J. A., Waga K., Rangel-Corona R., Monroy-Garcia A., Rocha-Zavaleta L., Urdiales-Ramos J., Weiss-Steider B., Haman A., Hugo P., Brousseau R., Hoang T. Implication of tyrosine kinase receptor and steel factor in cell density-dependent growth in cervical cancers and leukemias. Cancer Res. 2001; 61: 6281–6289
   PubMed Web of Science ®Google Scholar
• Hidalgo A., Schewe C., Petersen S., Salcedo M., Gariglio P., Schluns K., Dietel M., Petersen I. Human papilloma virus status and chromosomal imbalances in primary cervical carcinomas and tumour cell lines. Eur. J. Cancer. 2000; 36: 542–548
   PubMed Web of Science ®Google Scholar
• García A. M., Ortiz-Navarrete V. F., Mora-García M. L., Flores-Borja F., Diaz-Quinonez A., Isibasi-Araujo A., Trejo-Becerril C., Chacon-Salinas R., Hernández-Montes J., Granados-Arreola J., de Leo C., Weiss-Steider B. Identification of peptides presented by HLA class I molecules on cervical cancer cells with HPV-18 infection. Immunol. Lett. 1999; 67: 167–177
   PubMed Web of Science ®Google Scholar
• Cáceres-Cortés J. R., Rajotte D., Dumouchel J., Haddad P., Hoang T. Product of the Steel Locus suppresses apoptosis in hemopoietic cells. J. Biol. Chem. 1994; 269: 12084–12091
   PubMed Web of Science ®Google Scholar
• Penichet M. L., De la Cruz J. S., Shin S., Morrison S. L. A recombinant IgG3-(IL-2) fusion protein for the treatment of HER2/neu expressing tumors. Hum. Antibodies. 2001; 10: 43–49
   PubMedGoogle Scholar
• Baselga J., Hammond L. A. HER-targeted tyrosine-kinase inhibitors. Oncology 2002; 63: 6–16, Suppl1
   PubMed Web of Science ®Google Scholar
• Rossi E., Ubiali A., Balzarini P., Cadei M., Alpi F., Grigolati P. G. High-level detection of gene amplification and chromosome aneuploidy in extracted nuclei from paraffin-embedded tissue of human cancer using FISH: a new approach for retrospective studies. Eur. J. Histochem. 2005; 49: 53–58
   PubMed Web of Science ®Google Scholar
• Gazit A., Osherov N., Gilon C., Levitzki A., Tyrphostins B. Dimeric benzylidenemalononitrile tyrphostins: potent inhibitors of EGF receptor tyrosine kinase in vitro. J. Med. Chem. 1996; 39: 4905–4911
   PubMed Web of Science ®Google Scholar
• Gazit A., Osherov N., Posner I., Yaish P., Poradosu E., Gilon C., Levitzki A. Tyrphostins. 2. Heterocyclic and alpha-substituted benzylidenemalononitrile tyrphostins as potent inhibitors of EGF receptor and ErbB2/neu tyrosine kinases. J. Med. Chem. 1991; 34: 1896–1907
   PubMed Web of Science ®Google Scholar
• Stahl N., Yancopoulos G. D. The alphas, betas, and kinases of cytokine receptor complexes. Cell. 1993; 74: 587–590
   PubMed Web of Science ®Google Scholar
• O'Shea J. J., Gadina M., Schreiber R. D. Cytokine signaling in 2002: new surprises in the Jak/Stat pathway. Cell. 2002; 109: 121–131
   PubMed Web of Science ®Google Scholar
• David M., Wong L., Flavell R., Thompson S. A., Wells A., Larner A. C., Johnson G. R. STAT activation by epidermal growth factor (EGF) and amphiregulin. Requirement for the EGF receptor kinase, but not for tyrosine phosphorylation sites or JAK1. J. Biol. Chem. 1996; 271: 9185–9188
   PubMed Web of Science ®Google Scholar
• Xia L., Wang L., Chung A. S., Ivanov S. S., Ling M. Y., Dragoi A. M., Platt A., Gilmer T. M., Fu X. Y., Chin Y. E. Identification of both positive and negative domains within the epidermal growth factor receptor COOH-terminal region for signal transducer and activator of transcription (STAT) activation. J. Biol. Chem. 2002; 277: 30716–30723
   PubMed Web of Science ®Google Scholar
• Leaman D. W., Pisharody S., Flickinger T. W., Commane M. A., Schlessinger J., Kerr I. M., Levy D. E., Stark G. R. Roles of JAKs in activation of STATs and stimulation of c-fos gene expression by epidermal growth factor. Mol. Cell. Biol. 1996; 16: 369–375
   PubMed Web of Science ®Google Scholar
• Baselga J., Albanell J., Molina M. A., Arribas J. Mechanism of action of trastuzumab and scientific update. Semin. Oncol. 2001; 28: 4–11, (5 Suppl 16)
   PubMed Web of Science ®Google Scholar
• Hudziak R. M., Lewis G. D., Winget M., Fendley B. M., Shepard H. M., Ulrich A. p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor. Mol. Cell. Biol. 1989; 9: 1165–1172
   PubMed Web of Science ®Google Scholar
• Sauer G., Kurzeder C., Heilmann V., Kreienberg R., Deissler H. Immunotherapy and cancer vaccines in the management of breast cancer. Curr. Pharm. Des. 2005; 11: 3475–3483
   PubMed Web of Science ®Google Scholar
• Sliwkowski M. X., Lofgren J. A., Lewis G. D., Hotaling T. E., Fendly B. M., Fox J. A. Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin). Semin. Oncol. 1999; 26: 60–70
   PubMed Web of Science ®Google Scholar
• Lewis G. D., Lofgren J. A., McMurtrey A. E., Nuijens A., Fendly B. M., Bauer K. D., Sliwkowski M. X. Growth regulation of human breast and ovarian tumor cells by heregulin: evidence for the requirement of ErbB2 as a critical component in mediating heregulin responsiveness. Cancer Res. 1996; 56: 1457–1465
   PubMed Web of Science ®Google Scholar
• Lewis G. D., Figari I., Fendly B., Wong W. L., Carter P., Gorman C., Shepard H. M. Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies. Cancer Immunol. Immunother. 1993; 37: 255–263
   PubMed Web of Science ®Google Scholar
• Spiridon C. I., Ghetie M. A., Uhr J., Marches R., Li J. L., Shen G. L., Vitetta E. S. Targeting multiple Her-2 epitopes with monoclonal antibodies results in improved antigrowth activity of a human breast cancer cell line in vitro and in vivo. Clin. Cancer Res. 2002; 8: 1720–1730
   PubMed Web of Science ®Google Scholar
• Bouchard L., Lamarre L., Tremblay P. J., Jolicoeur P. Stochastic appearance of mammary tumors in transgenic mice carrying the MMTV/c-neu oncogene. Cell. 1989; 57: 931–936
   PubMed Web of Science ®Google Scholar
• Teicher B. A. Mutant, Transgenic, and Knockout Mouse Models. Tumor Models in Cancer Research. Humana Press Inc., Totowa, New JerseyUSA 2002; 195–222
   Google Scholar